BioNTech
repeated dosing enables tunable expansion of car cells | BioNTech
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
22 of 36
Related slides by other companies
Paysafe
Results
August 2022
summary recent highlights | Paysafe
Alkermes
Investor Day
March 2021
artistry determined selected as recommended phase dose for artistry efficacy expansion stage selection of based on totality of data including safety and efficacy during dose phase acceptable safety and tolerability profile consistent with the anticipated pharmacological effect and that observed with intravenous dose dependent increases in cell and cell activation and minimal increase in clinical benefit stable disease observed additional artistry data to be presented at future medical meeting phase efficacy expansion initiated based on totality of dose data regulatory cell natural killer pharmacodynamic | Alkermes
Bed Bath & Beyond
Results
October 2020
gross margin expansion | Bed Bath & Beyond
MaxCyte
Investor Presentation
April 2021
global partner of choice for non viral cell engineering technology | MaxCyte
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io